Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain

References

• PortenoyRKHagenNABreakthrough pain: definition, prevalence and characteristicsPain19904132732811697056
   PubMed Web of Science ®Google Scholar
• PayneRRecognition and diagnosis of breakthrough painPain Med20078Suppl 1S3S717280600
   PubMed Web of Science ®Google Scholar
• BrueraESchoellerTWenkRA prospective multicenter assessment of the Edmonton staging system for cancer painJ Pain Symptom Manage19951053483557673767
   PubMed Web of Science ®Google Scholar
• BennettDBurtonAWFishmanSConsensus panel recommendations for the assessment and management of breakthrough pain. Part 2: managementPharm Ther2005306354361
   Google Scholar
• Gomez-BatisteXMadridFMorenoFBreakthrough cancer pain: prevalence and characteristics in patients in Catalonia, SpainJ Pain Symptom Manage2002241455212183094
   PubMed Web of Science ®Google Scholar
• SvendsenKBAndersenSArnasonSBreakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanismsEur J Pain20059219520615737812
   PubMed Web of Science ®Google Scholar
• MercadanteSVillariPFerreraPCasuccioAOptimization of opioid therapy for preventing incident pain associated with bone metastasesJ Pain Symptom Manage200428550551015504626
   PubMed Web of Science ®Google Scholar
• MantyhPWCancer pain and its impact on diagnosis, survival and quality of lifeNat Rev Neurosci200671079780916988655
   PubMed Web of Science ®Google Scholar
• CollinsSLFauraCCMooreRAMcQuayHJPeak plasma concentrations after oral morphine: a systematic reviewJ Pain Symptom Manage19981663884029879164
   PubMed Web of Science ®Google Scholar
• MercadanteSVillariPFerreraPBianchiMCasuccioASafety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine doseJ Pain Symptom Manage200427435235915050663
   PubMed Web of Science ®Google Scholar
• JacksonKAshbyMKeechJPilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated painJ Pain Symptom Manage200223645045212067765
   PubMed Web of Science ®Google Scholar
• ColuzziPHSchwartzbergLConroyJDJrBreakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)Pain2001911–212313011240084
   PubMed Web of Science ®Google Scholar
• ZeppetellaGSublingual fentanyl citrate for cancer-related breakthrough pain: a pilot studyPalliat Med200115432332812054149
   PubMed Web of Science ®Google Scholar
• HagenNAFisherKStilesCSublingual methadone for the management of cancer-related breakthrough pain: a pilot studyJ Palliat Med200710233133717472503
   PubMed Web of Science ®Google Scholar
• FisherKStilesCHagenNACharacterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot studyJ Pain Symptom Manage200428661962515589088
   PubMed Web of Science ®Google Scholar
• PortenoyRKLesagePManagement of cancer painLancet199935391651695170010335806
   PubMed Web of Science ®Google Scholar
• MaguirePTsaiNKamalJCometta-MoriniCUptonCLoewGPharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptorsEur J Pharmacol199221322192251355735
   PubMed Web of Science ®Google Scholar
• McClainDAHugCCIntravenous fentanyl kineticsClin Pharmacol Ther19802811061147389247
   PubMed Web of Science ®Google Scholar
• StanleyTHHagueBMockDLOral transmucosal fentanyl citrate (lollipop) premedication in human volunteersAnesth Analg198969121272742164
   PubMed Web of Science ®Google Scholar
• ZhangHZhangJStreisandJBOral mucosal drug delivery: clinical pharmacokinetics and therapeutic applicationsClin Pharm2002419661680
   Google Scholar
• StreisandJBVarvelJRStanskiDRAbsorption and bioavailability of oral transmucosal fentanyl citrateAnesthesiology19917522232291859010
   PubMed Web of Science ®Google Scholar
• ShaiovaLLapinJMancoLSTolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositisSupport Care Cancer200412426827314750002
   PubMed Web of Science ®Google Scholar
• StanleyTHHagueBMockDLOral transmucosal fentanyl citrate (lollipop) premedication in human volunteersAnesth Analg198969121272742164
   PubMed Web of Science ®Google Scholar
• WeinbergDSInturrisiCEReidenbergBSublingual absorption of selected opioid analgesicsClin Pharm Ther1988443335342
   PubMed Web of Science ®Google Scholar
• BredenbergSNystromCIn-vitro evaluation of bioadhesion in particulate systems and possible improvement using interactive mixturesJ Pharm Pharmacol200355216917712631408
   PubMed Web of Science ®Google Scholar
• LennernasBHednerTHolmbergMBredenbergSNystromCLennernasHPharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident painBr J Clin Pharmacol200559224925315676050
   PubMed Web of Science ®Google Scholar
• BredenbergSDubergMLennernasBIn-vitro and in-vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substanceEur J Pharm Sci200320332733414592698
   PubMed Web of Science ®Google Scholar
• Sundell-BredenbergSNystromCThe possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronised drugEur J Pharm Sci200112328529511113648
   PubMed Web of Science ®Google Scholar
• NystromCWesterbergMThe use of ordered mixtures for improving the dissolution rate of low solubility compoundsJ Pharm Pharmacol19863831611652871148
   PubMed Web of Science ®Google Scholar
• WesterbergMNystromCPhysicochemical aspects of drug release XVII. The effect of drug surface area coverage to carrier materials on drug dissolution from ordered mixturesInt J Pharm1993901117
   Web of Science ®Google Scholar
• DarwishMKirbyMRobertsonPTracewellWJiangJGPharmacokinetic properties of fentanyl effervescent buccal tablets: a Phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 [mu] g in healthy adult volunteersClin Ther200628570771416861092
   PubMed Web of Science ®Google Scholar
• DarwishMKirbyMRobertsonPHellriegelEJiangJGSingle-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteersJ Clin Pharm20074715663
   Web of Science ®Google Scholar
• DarwishMKirbyMRobertsonPJrHellriegelEJiangJGComparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokineticsClin Pharm2006458843850
   Google Scholar
• DarwishMKirbyMRobertsonPTracewellWJiangJGAbsolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrateJ Clin Pharm2007473343350
   Web of Science ®Google Scholar
• DarwishMTemperoKKirbyMThompsonJRelative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 [mu] g: A single-dose, randomized, open-label, three-period study in healthy adult volunteersClin Ther200628571572416861093
   PubMed Web of Science ®Google Scholar
• LecybylRHannaMFentanyl buccal tablet: faster rescue analgesia for breakthrough pain?Future Oncol20073437537917661711
   PubMedGoogle Scholar
• DarwishMKirbyMRobertsonPTracewellWJiangJGAbsorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot studyClin Drug Investig2007279605611
   Web of Science ®Google Scholar
• EnglandRMaddocksMMandersonCZadora-ChrzastowskaSWilcockAHow practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinionBMJ Support Palliat Care201113349351
   Google Scholar
• LennernasBFrank-LissbrantILennernasHKanlknerKMDerrickRHowellJSublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized Phase II studyPalliat Med201024328629320015921
   PubMed Web of Science ®Google Scholar
• UberallMAMuller-SchwefeGHHSublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer painCurr Med Res Opin201171385139421561313
   PubMed Web of Science ®Google Scholar
• RauckRLTarkMReyesEEfficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer painCurr Med Res Opin200925122877288519814586
   PubMed Web of Science ®Google Scholar
• RauckRLTarkMReyesEEfficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer painCurr Med Res Opin200925122877288519814586
   PubMed Web of Science ®Google Scholar
• PortenoyRKTaylorDMessinaJTremmelLA randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid- treated patients with cancerClin J Pain200622980581117057563
   PubMed Web of Science ®Google Scholar
• SlatkinNEXieFMessinaJSegalTJFentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic painJ Support Oncol20075732733417708123
   PubMedGoogle Scholar
• MercadanteSFerreraPArcuriEThe use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary studySupport Care Cancer201119343543820882391
   PubMed Web of Science ®Google Scholar
• WeinsteinSMMessinaJXieFFentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer painCancer2009115112571257919373888
   PubMed Web of Science ®Google Scholar
• Drug Information Online http://www.drugs.com/search.php?searchterm=fentanyl+buccal+tabletsaccessed 30 May 2012
   Google Scholar
• MercadanteSFerreraPAdileCCasuccioAFentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background doseJ Pain Symptom Manage201142346446921477977
   PubMed Web of Science ®Google Scholar